RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Gritstone bio Stock

Gritstone bio P/S 2024

Gritstone bio P/S

24.32

Ticker

GRTS

ISIN

US39868T1051

WKN

A2N4RX

As of Nov 17, 2024, Gritstone bio's P/S ratio stood at 24.32, a 118.9% change from the 11.11 P/S ratio recorded in the previous year.

The Gritstone bio P/S history

Gritstone bio Aktienanalyse

What does Gritstone bio do?

Gritstone Oncology Inc. is a biotechnology company based in California, USA, that develops innovative cancer immunotherapies. It was founded in 2015 by Dr. Andrew Allen and Dr. Alex Chaudhuri, and has been listed on the Nasdaq stock exchange with the ticker "GRTS" since 2018. The founders previously worked in the field of immunotherapy at Roche and Takeda and recognized the potential of personalized cancer therapies using immunology and cancer genomics technologies. With funding of over $220 million from investors such as Versant Ventures, The Column Group, and Frazier Healthcare Partners, the company has experienced strong growth in recent years. Gritstone Oncology follows an integrated business model that includes innovative platform technologies for identifying tumor antigens and developing personalized immunotherapies. The company uses advanced sequencing technologies and data analysis methods to detect individual cancer mutations and develop tailored therapies. Gritstone Oncology has two main product categories: cancer immunotherapies and cancer diagnostics. The company is developing various immunotherapies for the treatment of cancer, including a novel SARS-CoV-2/COVID-19 vaccine based on the same platform as their cancer immunotherapies. Additionally, Gritstone Oncology has developed a proprietary platform for the development of bispecific antibodies, which can simultaneously target two different objectives. They are also developing personalized immunotherapies that specifically target an individual patient's cancer mutations. The company also offers diagnostic tests to identify cancer mutations and determine therapeutic options. These include GPS Cancer, a genomic test that enables personalized cancer diagnosis and therapy, and SLATE, a diagnostic test that analyzes the immune status of tumor cells and surrounding tissues to develop personalized immunotherapy. In conclusion, Gritstone Oncology has become a leading company in the field of personalized cancer immunotherapy. It has strong growth potential due to its innovative technologies and research, as well as its highly experienced leadership and employees. The company will continue to play a critical role in cancer research and therapy and has the potential to improve the lives of millions of people worldwide. Gritstone bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Gritstone bio's P/S Ratio

Gritstone bio's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Gritstone bio's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Gritstone bio's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Gritstone bio’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Gritstone bio stock

What is the price-to-earnings ratio of Gritstone bio?

The price-earnings ratio of Gritstone bio is currently 24.32.

How has the price-earnings ratio of Gritstone bio changed compared to last year?

The price-to-earnings ratio of Gritstone bio has increased by 118.9% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Gritstone bio high compared to other companies?

Yes, the price-to-earnings ratio of Gritstone bio is high compared to other companies.

How does an increase in the price-earnings ratio of Gritstone bio affect the company?

An increase in the price-earnings ratio of Gritstone bio would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Gritstone bio affect the company?

A decrease in the price-earnings ratio of Gritstone bio would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Gritstone bio?

Some factors that influence the price-earnings ratio of Gritstone bio are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Gritstone bio pay?

Over the past 12 months, Gritstone bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gritstone bio is expected to pay a dividend of 0 USD.

What is the dividend yield of Gritstone bio?

The current dividend yield of Gritstone bio is .

When does Gritstone bio pay dividends?

Gritstone bio pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gritstone bio?

Gritstone bio paid dividends every year for the past 0 years.

What is the dividend of Gritstone bio?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gritstone bio located?

Gritstone bio is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gritstone bio kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gritstone bio from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.

When did Gritstone bio pay the last dividend?

The last dividend was paid out on 11/17/2024.

What was the dividend of Gritstone bio in the year 2023?

In the year 2023, Gritstone bio distributed 0 USD as dividends.

In which currency does Gritstone bio pay out the dividend?

The dividends of Gritstone bio are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Gritstone bio

Our stock analysis for Gritstone bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gritstone bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.